Browsing Tag
Catalent
9 posts
Why Scholar Rock believes apitegromab could still become a major SMA therapy despite FDA delays
Scholar Rock targets a 2026 BLA resubmission and potential launch for apitegromab in spinal muscular atrophy. Discover what it means for the SMA market.
Can early access to GS010 in Israel accelerate GenSight’s push toward full regulatory approval?
GenSight Biologics secures Israeli early access for GS010 gene therapy in LHON. Find out how this could reshape access, manufacturing, and investor outlook.
Factory shock at Clayton: Why Novo Nordisk is cutting jobs even as it expands in America’s GLP-1 boom
Find out how Novo Nordisk’s U.S. factory job cuts fit into its $4.1 billion expansion—and what it means for Wegovy, Ozempic, and GLP-1 growth in 2025.
Made Scientific and Syenex team up to reshape T cell therapy manufacturing with advanced bioengineering platforms
Made Scientific and Syenex partner to scale T cell therapy manufacturing with UltraCell and RapidCell systems, aiming to cut costs and speed timelines.
FDA delay shifts Neurizon Therapeutics (ASX: NUZ) ALS trial start — Can Q4 still deliver a win?
FDA delays decision on Neurizon’s NUZ-001 ALS trial to October, but manufacturing, regulatory, and trial readiness milestones keep Q4 start within reach.
GenSight Biologics completes LUMEVOQ tech transfer to Catalent to enable global clinical expansion
GenSight Biologics advances gene therapy LUMEVOQ® through strategic manufacturing transfer to Catalent, bolstering regulatory readiness and clinical scale-up.
Novo Nordisk set to finalize $11bn acquisition of Catalent manufacturing sites
Novo Nordisk is set to finalise its acquisition of three Catalent manufacturing sites, marking a pivotal step in…
Novo Nordisk announces $11bn acquisition of fill-finish sites to boost global manufacturing
In a strategic move to enhance its global manufacturing capabilities, Novo Nordisk has announced a significant acquisition from…
Catalent wins contract to manufacture AZD1222 COVID-19 vaccine candidate
US-based Catalent said that its subsidiary Catalent Biologics has bagged a contract to provide vial filling and packaging…